Key result
Sintilimab plus anlotinib achieves ~77% tumor reduction in a chemotherapy-intolerant patient with advanced sarcoma.
Why the study?
Does sintilimab plus anlotinib improve tumor response in a patient with advanced undifferentiated pleomorphic sarcoma intolerant to chemotherapy?
Does sintilimab plus anlotinib improve tumor response in a patient with advanced undifferentiated pleomorphic sarcoma intolerant to chemotherapy?
Sintilimab plus anlotinib may be a potential treatment option for chemotherapy-ineligible advanced undifferentiated pleomorphic sarcoma.
May suggest an option for chemotherapy-ineligible advanced UPS; hypothesis-generating and should not yet change practice.
This report describes the case of a 73‐year‐old woman with advanced undifferentiated pleomorphic sarcoma (UPS) who was intolerant to chemotherapy. Following amputation, she received sintilimab plus anlotinib and achieved a partial response with 76.6% tumor reduction. This combination may be a potential option for chemotherapy‐ineligible advanced UPS, warranting further investigation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question. Sintilimab plus anlotinib resulted in a partial response with 76.6% tumor reduction in a patient with advanced undifferentiated pleomorphic sarcoma intolerant to chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: